Top

Published in:

Open Access 01-12-2021 | SARS-CoV-2 | Commentary

Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?

Author: Cecilia Söderberg-Nauclér

Published in: Immunity & Ageing | Issue 1/2021

Abstract

The majority of people infected with SARS-CoV-2 are asymptomatic or have mild to moderate symptoms. However, for unknown reasons, about 15 % have severe pneumonia requiring hospital care and oxygen support, and about 5 % develop acute respiratory distress syndrome, septic shock, and multiorgan failure that result in a high mortality rate. The risk of severe COVID-19 is highest among those who are over 70 years of age. Why severe COVID-19 develops in some people but not others is not understood. Could some cases involve reactivation of latent cytomegalovirus (CMV)?

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. https://doi.org/10.1016/S0140-6736(20)30566-3.CrossRefPubMedPubMedCentral

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. https://doi.org/10.1016/S0140-6736(20)30183-5.CrossRefPubMedPubMedCentral

O’Driscoll M, Dos Santos GR, Wang L, Cummings DAT, Azman AS, Paireau J, Fontanet A, Cauchemez S, Salje H: Age-specific mortality and immunity patterns of SARS-CoV-2. Nature 2020.10.1038/s41586-020-2918-0.

Salje H, Tran Kiem C, Lefrancq N, Courtejoie N, Bosetti P, Paireau J, Andronico A, Hoze N, Richet J, Dubost CL, et al. Estimating the burden of SARS-CoV-2 in France. Science. 2020;369:208–11. https://doi.org/10.1126/science.abc3517.CrossRefPubMedPubMedCentral

Wikby A, Johansson B, Olsson J, Lofgren S, Nilsson BO, Ferguson F. Expansions of peripheral blood CD8 T-lymphocyte subpopulations and an association with cytomegalovirus seropositivity in the elderly: the Swedish NONA immune study. Exp Gerontol. 2002;37:445–53.CrossRefPubMed

Adriaensen W, Pawelec G, Vaes B, Hamprecht K, Derhovanessian E, van Pottelbergh G, Degryse JM, Mathei C. CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study. J Gerontol A Biol Sci Med Sci. 2017;72:1155–62. https://doi.org/10.1093/gerona/glw215.CrossRefPubMed

Roberts ET, Haan MN, Dowd JB, Aiello AE. Cytomegalovirus antibody levels, inflammation, and mortality among elderly Latinos over 9 years of follow-up. Am J Epidemiol. 2010;172:363–71. https://doi.org/10.1093/aje/kwq177.CrossRefPubMedPubMedCentral

Wang GC, Kao WH, Murakami P, Xue QL, Chiou RB, Detrick B, McDyer JF, Semba RD, Casolaro V, Walston JD, Fried LP. Cytomegalovirus infection and the risk of mortality and frailty in older women: a prospective observational cohort study. Am J Epidemiol. 2010;171:1144–52. https://doi.org/10.1093/aje/kwq062.CrossRefPubMedPubMedCentral

Karrer U, Sierro S, Wagner M, Oxenius A, Hengel H, Koszinowski UH, Phillips RE, Klenerman P. Memory inflation: continuous accumulation of antiviral CD8 + T cells over time. J Immunol. 2003;170:2022–9. https://doi.org/10.4049/jimmunol.170.4.2022.CrossRefPubMed

10.

Chidrawar S, Khan N, Wei W, McLarnon A, Smith N, Nayak L, Moss P. Cytomegalovirus-seropositivity has a profound influence on the magnitude of major lymphoid subsets within healthy individuals. Clin Exp Immunol. 2009;155:423–32. https://doi.org/10.1111/j.1365-2249.2008.03785.x.CrossRefPubMedPubMedCentral

11.

Lindau P, Mukherjee R, Gutschow MV, Vignali M, Warren EH, Riddell SR, Makar KW, Turtle CJ, Robins HS. Cytomegalovirus Exposure in the Elderly Does Not Reduce CD8 T Cell Repertoire Diversity. J Immunol. 2019;202:476–83. https://doi.org/10.4049/jimmunol.1800217.CrossRefPubMed

12.

Powers C, DeFilippis V, Malouli D, Fruh K. Cytomegalovirus immune evasion. Curr Top Microbiol Immunol. 2008;325:333–59.PubMed

13.

Merani S, Pawelec G, Kuchel GA, McElhaney JE. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. Front Immunol. 2017;8:784. https://doi.org/10.3389/fimmu.2017.00784.CrossRefPubMedPubMedCentral

14.

Moss P. “The ancient and the new”: is there an interaction between cytomegalovirus and SARS-CoV-2 infection? Immun Ageing. 2020;17:14. https://doi.org/10.1186/s12979-020-00185-x.CrossRefPubMedPubMedCentral

15.

Kadambari S, Klenerman P, Pollard AJ. Why the elderly appear to be more severely affected by COVID-19: The potential role of immunosenescence and CMV. Rev Med Virol. 2020;30:e2144. https://doi.org/10.1002/rmv.2144.CrossRefPubMed

16.

Soderberg-Naucler C. Does cytomegalovirus play a causative role in the development of various inflammatory diseases and cancer? J Intern Med. 2006;259:219–46. https://doi.org/10.1111/j.1365-2796.2006.01618.x.CrossRefPubMed

17.

Belga S, MacDonald C, Chiang D, Kabbani D, Shojai S, Abraldes JG, Cervera C: Donor graft CMV-serostatus and the risk of arterial and venous thrombotic events in seronegative recipients after non-thoracic solid organ transplantation. Clin Infect Dis 2020.10.1093/cid/ciaa125.

18.

Simanek AM, Dowd JB, Pawelec G, Melzer D, Dutta A, Aiello AE. Seropositivity to cytomegalovirus, inflammation, all-cause and cardiovascular disease-related mortality in the United States. PLoS One. 2011;6:e16103. https://doi.org/10.1371/journal.pone.0016103.CrossRefPubMedPubMedCentral

19.

Catalano-Pons C, Quartier P, Leruez-Ville M, Kaguelidou F, Gendrel D, Lenoir G, Casanova JL, Bonnet D. Primary cytomegalovirus infection, atypical Kawasaki disease, and coronary aneurysms in 2 infants. Clin Infect Dis. 2005;41:e53-56. https://doi.org/10.1086/432578.CrossRefPubMed

20.

Consiglio CR, Cotugno N, Sardh F, Pou C, Amodio D, Rodriguez L, Tan Z, Zicari S, Ruggiero A, Pascucci GR, et al. The Immunology of Multisystem Inflammatory Syndrome in Children with COVID-19. Cell. 2020;183(968):981. https://doi.org/10.1016/j.cell.2020.09.016 e967.CrossRef

21.

Ahlfors K. IgG antibodies to cytomegalovirus in a normal urban Swedish population. Scand J Infect Dis. 1984;16:335–7.CrossRefPubMed

22.

Griffiths P, Baraniak I, Reeves M. The pathogenesis of human cytomegalovirus. J Pathol. 2015;235:288–97. https://doi.org/10.1002/path.4437.CrossRefPubMed

23.

Zuhair M, Smit GSA, Wallis G, Jabbar F, Smith C, Devleesschauwer B, Griffiths P. Estimation of the worldwide seroprevalence of cytomegalovirus: A systematic review and meta-analysis. Rev Med Virol. 2019;29:e2034. https://doi.org/10.1002/rmv.2034.CrossRefPubMed

24.

Staras SA, Dollard SC, Radford KW, Flanders WD, Pass RF, Cannon MJ. Seroprevalence of cytomegalovirus infection in the United States, 1988–1994. Clin Infect Dis. 2006;43:1143–51. https://doi.org/10.1086/508173.CrossRefPubMed

25.

Tookey PA, Ades AE, Peckham CS. Cytomegalovirus prevalence in pregnant women: the influence of parity. Arch Dis Child. 1992;67:779–83. https://doi.org/10.1136/adc.67.7_spec_no.779.CrossRefPubMedPubMedCentral

26.

Hjelmesaeth J, Hartmann A, Leivestad T, Holdaas H, Sagedal S, Olstad M, Jenssen T. The impact of early-diagnosed new-onset post-transplantation diabetes mellitus on survival and major cardiac events. Kidney Int. 2006;69:588–95.CrossRefPubMed

27.

Johnsen JI, Baryawno N, Soderberg-Naucler C. Is human cytomegalovirus a target in cancer therapy? Oncotarget. 2011;2:1329–38.CrossRefPubMedPubMedCentral

28.

Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr Top Microbiol Immunol. 2008;325:297–313.PubMed

29.

Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell. 1997;91:119–26.CrossRefPubMed

30.

Dmitrienko S, Balshaw R, Machnicki G, Shapiro RJ, Keown PA. Probabilistic modeling of cytomegalovirus infection under consensus clinical management guidelines. Transplantation. 2009;87:570–7. https://doi.org/10.1097/TP.0b013e3181949e09.CrossRefPubMed

31.

Atabani SF, Smith C, Atkinson C, Aldridge RW, Rodriguez-Peralvarez M, Rolando N, Harber M, Jones G, O’Riordan A, Burroughs AK, et al. Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant. 2012;12:2457–64. https://doi.org/10.1111/j.1600-6143.2012.04087.x.CrossRefPubMedPubMedCentral

32.

Poole E, Juss JK, Krishna B, Herre J, Chilvers ER, Sinclair J. Alveolar Macrophages Isolated Directly From Human Cytomegalovirus (HCMV)-Seropositive Individuals Are Sites of HCMV Reactivation In Vivo. J Infect Dis. 2015;211:1936–42. https://doi.org/10.1093/infdis/jiu837.CrossRefPubMed

33.

van der Bij W, Speich R. Management of cytomegalovirus infection and disease after solid-organ transplantation. Clin Infect Dis. 2001;33(Suppl 1):S32-37. https://doi.org/10.1086/320902.CrossRefPubMed

34.

Westall GP, Michaelides A, Williams TJ, Snell GI, Kotsimbos TC. Bronchiolitis obliterans syndrome and early human cytomegalovirus DNAaemia dynamics after lung transplantation. Transplantation. 2003;75:2064–8.CrossRefPubMed

35.

Potena L, Valantine HA. Cytomegalovirus-associated allograft rejection in heart transplant patients. Curr Opin Infect Dis. 2007;20:425–31.CrossRefPubMed

36.

Fateh-Moghadam S, Bocksch W, Wessely R, Jager G, Hetzer R, Gawaz M. Cytomegalovirus infection status predicts progression of heart-transplant vasculopathy. Transplantation. 2003;76:1470–4.CrossRefPubMed

37.

Johansson I, Andersson R, Friman V, Selimovic N, Hanzen L, Nasic S, Nystrom U, Sigurdardottir V. Cytomegalovirus infection and disease reduce 10-year cardiac allograft vasculopathy-free survival in heart transplant recipients. BMC Infect Dis. 2015;15:582. https://doi.org/10.1186/s12879-015-1321-1.CrossRefPubMedPubMedCentral

38.

Hjelmesaeth J, Sagedal S, Hartmann A, Rollag H, Egeland T, Hagen M, Nordal KP, Jenssen T. Asymptomatic cytomegalovirus infection is associated with increased risk of new-onset diabetes mellitus and impaired insulin release after renal transplantation. Diabetologia. 2004;47:1550–6.CrossRefPubMed

39.

Potena L, Grigioni F, Magnani G, Lazzarotto T, Musuraca AC, Ortolani P, Coccolo F, Fallani F, Russo A, Branzi A. Prophylaxis versus preemptive anti-cytomegalovirus approach for prevention of allograft vasculopathy in heart transplant recipients. J Heart Lung Transplant. 2009;28:461–7. https://doi.org/10.1016/j.healun.2009.02.009.CrossRefPubMed

40.

Ruttmann E, Geltner C, Bucher B, Ulmer H, Hofer D, Hangler HB, Semsroth S, Margreiter R, Laufer G, Muller LC. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation. Transplantation. 2006;81:1415–20. https://doi.org/10.1097/01.tp.0000209439.27719.ed.CrossRefPubMed

41.

Hui J, Qu YY, Tang N, Liu YM, Zhong H, Wang LM, Feng Q, Li Z, He F. Association of cytomegalovirus infection with hypertension risk: a meta-analysis. Wien Klin Wochenschr. 2016;128:586–91. https://doi.org/10.1007/s00508-016-0977-x.CrossRefPubMedPubMedCentral

42.

Sherman S, Eytan O, Justo D. Thrombosis associated with acute cytomegalovirus infection: a narrative review. Arch Med Sci. 2014;10:1186–90. https://doi.org/10.5114/aoms.2014.47828.CrossRefPubMedPubMedCentral

43.

Elkind MS, Ramakrishnan P, Moon YP, Boden-Albala B, Liu KM, Spitalnik SL, Rundek T, Sacco RL, Paik MC. Infectious burden and risk of stroke: the northern Manhattan study. Arch Neurol. 2010;67:33–8. https://doi.org/10.1001/archneurol.2009.271.CrossRefPubMed

44.

Kutza AS, Muhl E, Hackstein H, Kirchner H, Bein G. High incidence of active cytomegalovirus infection among septic patients. Clin Infect Dis. 1998;26:1076–82.CrossRefPubMed

45.

Reeves M, Sissons P, Sinclair J. Reactivation of human cytomegalovirus in dendritic cells. Discov Med. 2005;5:170–4.PubMed

46.

Li X, Huang Y, Xu Z, Zhang R, Liu X, Li Y, Mao P. Cytomegalovirus infection and outcome in immunocompetent patients in the intensive care unit: a systematic review and meta-analysis. BMC Infect Dis. 2018;18:289. https://doi.org/10.1186/s12879-018-3195-5.CrossRefPubMedPubMedCentral

47.

Cowley NJ, Owen A, Shiels SC, Millar J, Woolley R, Ives N, Osman H, Moss P, Bion JF. Safety and Efficacy of Antiviral Therapy for Prevention of Cytomegalovirus Reactivation in Immunocompetent Critically Ill Patients: A Randomized Clinical Trial. JAMA Intern Med. 2017;177:774–83. https://doi.org/10.1001/jamainternmed.2017.0895.CrossRefPubMedPubMedCentral

48.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et al: Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 2020.10.1172/JCI137244.

49.

McSharry BP, Avdic S, Slobedman B. Human cytomegalovirus encoded homologs of cytokines, chemokines and their receptors: roles in immunomodulation. Viruses. 2012;4:2448–70. https://doi.org/10.3390/v4112448.CrossRefPubMedPubMedCentral

50.

Forte E, Swaminathan S, Schroeder MW, Kim JY, Terhune SS, Hummel M: Tumor Necrosis Factor Alpha Induces Reactivation of Human Cytomegalovirus Independently of Myeloid Cell Differentiation following Posttranscriptional Establishment of Latency. MBio 2018, 9.10.1128/mBio.01560-18.

51.

Ma N, Mi H, Loesch K, Pollard R. Human cytomegalovirus-induced immunosuppression. Relationship to tumor necrosis factor-dependent release of arachidonic acid and prostaglandin E2 in human monocytes. J Clin Invest. 1996;97:2635–41.CrossRef

52.

Qiu H, Straat K, Rahbar A, Wan M, Soderberg-Naucler C, Haeggstrom JZ. Human CMV infection induces 5-lipoxygenase expression and leukotriene B4 production in vascular smooth muscle cells. J Exp Med. 2008;205:19–24. https://doi.org/10.1084/jem.20070201.CrossRefPubMedPubMedCentral

53.

Slinger E, Maussang D, Schreiber A, Siderius M, Rahbar A, Fraile-Ramos A, Lira SA, Soderberg-Naucler C, Smit MJ: HCMV-encoded chemokine receptor US28 mediates proliferative signaling through the IL-6-STAT3 axis. Sci Signal 2010, 3:ra58.10.1126/scisignal.2001180.

54.

Streblow DN, Söderberg-Nauclér C, Nelson JA, Vieira J, Smith P, Wakabayashi E, Ruchti F, Mattison K, Altschuler Y. The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration. Cell 1999, 99.

55.

Reeves MB, Compton T. Inhibition of inflammatory interleukin-6 activity via extracellular signal-regulated kinase-mitogen-activated protein kinase signaling antagonizes human cytomegalovirus reactivation from dendritic cells. J Virol. 2011;85:12750–8. https://doi.org/10.1128/JVI.05878-11.CrossRefPubMedPubMedCentral

56.

Almeida GD, Porada CD, St Jeor S, Ascensao JL. Human cytomegalovirus alters interleukin-6 production by endothelial cells. Blood. 1994;83:370–6.CrossRefPubMed

57.

Compton T, Kurt-Jones EA, Boehme KW, Belko J, Latz E, Golenbock DT, Finberg RW. Human cytomegalovirus activates inflammatory cytokine responses via CD14 and Toll-like receptor 2. J Virol. 2003;77:4588–96.CrossRefPubMedPubMedCentral

58.

Sa Ribero M, Jouvenet N, Dreux M, Nisole S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020;16:e1008737. https://doi.org/10.1371/journal.ppat.1008737.CrossRefPubMedPubMedCentral

59.

Murray MJ, Peters NE, Reeves MB: Navigating the Host Cell Response during Entry into Sites of Latent Cytomegalovirus Infection. Pathogens 2018, 7.10.3390/pathogens7010030.

60.

Michelson S, Alcami J, Kim SJ, Danielpour D, Bachelerie F, Picard L, Bessia C, Paya C, Virelizier JL. Human cytomegalovirus infection induces transcription and secretion of transforming growth factor beta 1. J Virol. 1994;68:5730–7.CrossRefPubMedPubMedCentral

61.

Shimamura M, Murphy-Ullrich JE, Britt WJ. Human cytomegalovirus induces TGF-beta1 activation in renal tubular epithelial cells after epithelial-to-mesenchymal transition. PLoS Pathog. 2010;6:e1001170. https://doi.org/10.1371/journal.ppat.1001170.CrossRefPubMedPubMedCentral

62.

Merrill JT, Erkan D, Winakur J, James JA. Emerging evidence of a COVID-19 thrombotic syndrome has treatment implications. Nat Rev Rheumatol. 2020;16:581–9. https://doi.org/10.1038/s41584-020-0474-5.CrossRefPubMedPubMedCentral

63.

Rahbar A, Soderberg-Naucler C. Human cytomegalovirus infection of endothelial cells triggers platelet adhesion and aggregation. J Virol. 2005;79:2211–20. https://doi.org/10.1128/JVI.79.4.2211-2220.2005.CrossRefPubMedPubMedCentral

64.

Le Balc’h P, Pinceaux K, Pronier C, Seguin P, Tadie JM, Reizine F: Herpes simplex virus and cytomegalovirus reactivations among severe COVID-19 patients. Crit Care 2020, 24:530.10.1186/s13054-020-03252-3.

65.

Geisen WR, Berger J, Schwartz C, Reddy A, Rai B, Wadih G, Peck J. Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy. IDCases. 2020;22:e00962. https://doi.org/10.1016/j.idcr.2020.e00962.CrossRefPubMedPubMedCentral

66.

Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, Rawlings SA, Sutherland A, Premkumar L, Jadi RS, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181:1489–501. https://doi.org/10.1016/j.cell.2020.05.015. e1415.CrossRefPubMedPubMedCentral

67.

Neidleman J, Luo X, Frouard J, Xie G, Gill G, Stein ES, McGregor M, Ma T, George AF, Kosters A, et al. SARS-CoV-2-Specific T Cells Exhibit Phenotypic Features of Helper Function, Lack of Terminal Differentiation, and High Proliferation Potential. Cell Rep Med. 2020;1:100081. https://doi.org/10.1016/j.xcrm.2020.100081.CrossRefPubMedPubMedCentral

68.

Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183(158–168):e114. https://doi.org/10.1016/j.cell.2020.08.017.CrossRef

69.

Willette AA, Willette SA, Wang Q, Pappas C, Klinedinst BS, Le S, Larsen B, Pollpeter A, Brenner N, Waterboer T: Antibody response to infectious diseases and other factors accurately predict COVID-19 infection and severity risk 10–14 years later: a retrospective UK Biobank cohort study. medRxiv 2020.10.1101/2020.06.09.20127092.

70.

Shrock E, Fujimura E, Kula T, Timms RT, Lee IH, Leng Y, Robinson ML, Sie BM, Li MZ, Chen Y, et al: Viral epitope profiling of COVID-19 patients reveals cross-reactivity and correlates of severity. Science 2020.10.1126/science.abd4250.

71.

Frasca D, Diaz A, Romero M, Landin AM, Blomberg BB. Cytomegalovirus (CMV) seropositivity decreases B cell responses to the influenza vaccine. Vaccine. 2015;33:1433–9. https://doi.org/10.1016/j.vaccine.2015.01.071.CrossRefPubMedPubMedCentral

72.

Derhovanessian E, Theeten H, Hahnel K, Van Damme P, Cools N, Pawelec G. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. Vaccine. 2013;31:685–90. https://doi.org/10.1016/j.vaccine.2012.11.041.CrossRefPubMed

73.

Ladds E, Rushforth A, Wieringa S, Taylor S, Rayner C, Husain L, Greenhalgh T. Persistent symptoms after Covid-19: qualitative study of 114 “long Covid” patients and draft quality principles for services. BMC Health Serv Res. 2020;20:1144. https://doi.org/10.1186/s12913-020-06001-y.CrossRefPubMedPubMedCentral

Title: Does reactivation of cytomegalovirus contribute to severe COVID-19 disease?
Author: Cecilia Söderberg-Nauclér
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: SARS-CoV-2
COVID-19
Published in: Immunity & Ageing / Issue 1/2021
Electronic ISSN: 1742-4933
DOI: https://doi.org/10.1186/s12979-021-00218-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2021

Obesity and COVID-19: what makes obese host so vulnerable?

Human endogenous retroviruses and ageing

Analysis of the heterogeneity of the BCR H-CDR3 repertoire in the bone marrow and spleen of 3-, 12-, and 20-month old mice

Sex- and age‐dependent alterations of splenic immune cell profile and NK cell phenotypes and function in C57BL/6J mice

CMV infection, CD19+ B cell depletion, and Lymphopenia as predictors for unexpected admission in the institutionalized elderly

Quantification of dendritic cell subsets in human thymus tissues of various ages

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials